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Transmission of avian influenza virus into human
populations has the potential to cause pandemic
outbreaks. A major determinant of species tropism
is the identity of amino acid 627 in the PB2 subunit
of the heterotrimeric influenza polymerase; glutamic
acid predominates in avian PB2, whereas lysine
occupies this position in human isolates. We show
that a dominant inhibitory activity in human cells po-
tently and selectively restricts the function of poly-
merases containing an avian-like PB2 with glutamic
acid at residue 627. Restricted polymerases fail to
assemble into ribonucleoprotein complexes, result-
ing in decreased genome transcription, replication,
and virus production without any significant effect
on relative viral infectivity. Understanding the molec-
ular basis of this species-specific restriction should
provide strategies to prevent and treat avian influ-
enza outbreaks in humans.
INTRODUCTION
Recurring outbreaks of highly pathogenic H5N1 avian influenza
virus in domestic and wild bird populations pose a serious threat
to public health.Outbreaksdecimate bird populations andcan re-
sult in severe and often fatal avian influenza virus infections in hu-
mans (Chen et al., 2006b, 2005; Hatta et al., 2001; Maines et al.,
2005). Because transmissionof influenza virus frombird to human
populations has the potential to establish newpandemics, under-
standing species tropism and virulence of these viruses is critical
to prevention and treatment efforts (Subbarao et al., 2006).
Along with its central role in viral replication and gene expres-
sion, the influenza virus RNA-dependent RNA polymerase is
a major determinant of viral tropism and pathogenicity. The influ-
enza polymerase is a 250 kD heterotrimer composed of three
polypeptides: PB1, PB2, and PA. The polymerase associates
with viral RNA and the viral nucleoprotein (NP) to form ribonu-
cleoprotein (RNP) complexes that mediate transcription via
a cap-snatching technique that utilizes short host-derivedCell Ho7mG-capped RNAs as primers for synthesis of influenza mRNAs
(see Figure S1A available online) (Elton et al., 2005). RNPs also
direct replication of the minus-sense viral RNA genome (vRNA)
through a plus-sense complementary RNA (cRNA) intermediate.
Following replication, vRNA segments are packaged as vRNPs
into newly budding virions. The PB2 subunit has long been iden-
tified as a host-range determinant (Almond, 1977); replication in
human and avian systems depends on the identity of amino acid
627 (Subbarao et al., 1993). Glutamic acid predominates at
position 627 in avian PB2, whereas lysine is present almost
exclusively at this position in human isolates (Chen et al.,
2006a). The presence of a lysine at residue 627 enhances viral
replication and pathogenicity in mammalian model systems
(Hatta et al., 2001; Munster et al., 2007; Salomon et al., 2006)
and is associated with lethality in humans infected with H5N1
and H7N7 avian viruses (Fouchier et al., 2004; Gao et al.,
1999). Conversely, the presence of a glutamic acid at this posi-
tion severely attenuates replication efficiency and pathogenicity
in mammalian systems (Hatta et al., 2001; Shinya et al., 2004).
Amino acid 627 lies outside of the identified functional do-
mains and subunit-binding sites in PB2, and the molecular basis
for restricted polymerase function has not been established. By
analyzing the function of PB2 variants in transient hetero-
karyons formed between human and avian cells, we show
here that a dominant inhibitory activity in human cells potently
and selectively restricts the function of avian-like PB2 K627E.
This inhibitor dramatically reduces viral production by polymer-
ases containing PB2 K627E without reducing the relative infec-
tivity of the virions that are produced. The restricted polymerase
fails to both bind NP and assemble into vRNP complexes in hu-
man cells, resulting in decreased genome transcription, replica-
tion, and virus production. However, both WT and mutant PB2
bind to NP when expressed alone, suggesting that it is the con-
formation of the polymerase trimer that is altered by changes at
PB2 residue 627. The blockade is relieved during late stages of
viral infection, allowing assembly of PB2 K627E-containing
vRNP and virus budding. Our data indicate that the blockade
targets the polymerase at an early stage during replication.
Thus, adaptation of avian PB2 to replication in human cells
involves escape from species-specific restriction(s) of polymer-
ase function. Exploiting this inhibitory activity may provide for
new prevention strategies.st & Microbe 4, 111–122, August 14, 2008 ª2008 Elsevier Inc. 111
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Dominant Restriction of Avian-like Influenza
Polymerase in Human Cells
The avian-signature glutamic acid at position 627 in PB2 has
been associated with reduced virus replication in mammalian
cells, mice, ferrets, and humans (Clements et al., 1992; Fouchier
et al., 2004; Gao et al., 1999; Hatta et al., 2001; Munster et al.,
2007; Salomon et al., 2006; Shinya et al., 2004; Subbarao
et al., 1993). To determine whether this reduction results from
decreased virion production, viral infectivity, or a combination
of the two, we measured the infectivity of normalized amounts
of recombinant virus. Recombinant A/WSN/33 virus was pro-
duced in 293T cells in the presence of PB2 containing a lysine
at position 627 (WT) or the PB2 mutant containing glutamic
acid at this position (K627E). For simplicity, we refer to PB2
K627E as avian-like, recognizing that additional amino acid dif-
ferences might exist between PB2 from A/WSN/33 and various
avian strains. The use of a plasmid-based reverse genetics sys-
tem permitted analysis of individual residues in isogenic virus
backgrounds and initially ensured equivalent expression of WT
and K627E PB2 proteins independent of their functionality. Pla-
que assays were performed on canine (MDCK) cells, which dis-
play only a minor dependence on PB2 amino acid 627 for the
lab-adapted strain A/WSN/33 (data not shown) and recent
H5N1 isolates (Hatta et al., 2007; Labadie et al., 2007; Massin
et al., 2005; Shinya et al., 2004), whereas other isolates contain-
ing a glutamic acid at position 627 do not replicate efficiently in
MDCK cells (Subbarao et al., 1993). The PB2 K627E mutation
reduced the infectious plaque assay titer to only1% compared
to that of WT, similar to previous observations (Figure 1A). This
decreased infectious titer was associated with a concomitant
decrease in virion production. PB2 K627E viral supernatants
contained 4.6% of the hemagglutination activity possessed by
WT (data not shown). Both WT and K627E PB2 displayed similar
infectious titers when the viral inoculumwas normalized by hem-
agglutination titer (Figure 1A). Thus, the PB2 K627E mutation
reduces virus replication primarily by reducing the production
of viral particles, whereas the particles that are produced are
as infectious as WT.
To further understand the defects associated with a polymer-
ase containing PB2 K627E, we utilized a cell-based polymerase
activity assay to determine the species-specific amino acid
requirements at this position (Figure S1B). Human 293T cells
were transfected with vectors expressing PB1, PA, NP, and
WT or mutant TAP-tagged PB2 (PB2-TAP) cloned from the
mouse-adapted lab strain A/WSN/33 based on a human influ-
enza isolate. WT PB2, in the context of human isolates, contains
a lysine at position 627. The presence of a C-terminal TAP tag on
PB2 does not significantly alter function (Engelhardt et al., 2005;
Fodor and Smith, 2004). Cells were cotransfected with a reporter
vector expressing minus-sense luciferase RNA flanked by neur-
aminidase viral RNA sequences (Regan et al., 2006). The vRNA-
luciferase reporter is replicated and transcribed only in the
presence of functional influenza polymerase. Polymerase recon-
stituted with WT PB2 produced significant amounts of luciferase
asmeasured by a luciferase-activity assay, whereas control cells
transfected as above but with reporter alone or with polymerase-
expression plasmids lacking PB2 (DPB2) produced only back-112 Cell Host & Microbe 4, 111–122, August 14, 2008 ª2008 Elsevieground levels of luciferase (<0.5%) (Figure 1B). Mutation of
PB2 to the avian-like K627E severely impaired luciferase produc-
tion; luciferase activity was reduced to only 2.5% WT activity,
in agreement with previous reports demonstrating reduced func-
tion of polymerase containing a glutamic acid at PB2 residue 627
in human cells (Labadie et al., 2007; Naffakh et al., 2000;
Salomon et al., 2006). The conservative PB2 K627R mutation
functioned at levels similar to WT. K627H and K627A mutations
reduced polymerase activity, although these mutants still re-
tained 25% WT activity. The K627D mutation demonstrated
themost profound defect, with polymerase activity indistinguish-
able from background. Western blot analysis detected similar
levels of NP and WT or mutant PB2 expression, suggesting
that differences in polymerase function were not the result of dif-
ferential protein expression, stability, or transfection efficiency.
Similar results were observed when experiments were repeated
in the African green monkey cells Cos7 (Figure 1B) and human
HeLa cells (Figure S2), indicating generally decreased function
of avian-like PB2 K627E in primate cells. In addition, similar
results were observed whether polymerase activity assays
were performed at 33C, 37C, or 41C (data not shown). These
data show that a basic residue at position 627 is critical for
production of viral mRNA and that acidic residues at this position
severely compromise transcriptional activity in primate cells.
To gain further insight into the mechanism of restriction, we in-
vestigated polymerase activity at the cellular level. The lucifer-
ase-based assays measure polymerase activity in bulk, making
it unclear if the polymerase activity associated with PB2 K627E
is equally impaired throughout the entire cell population or if
the reduction in activity as compared to wild-type results from
a stochastic event where only a subset of cells restrict polymer-
ase function. To differentiate these two possibilities, we mea-
sured polymerase activity utilizing a vNS-GFP reporter plasmid
(Figure S3). GFP was produced by WT polymerase less than
20 hr posttransfection and was saturated within 48 hr. By con-
trast, in cells expressing PB2 K627E GFP appeared with delayed
kinetics at lower levels throughout the entire population. RFP
was expressed equivalently in both transfections, and GFP
was present in a similar number of cells at 70 hr posttransfection
for WT and PB2 K627E, indicating equivalent transfection effi-
ciencies. These data suggest that the reduction in polymerase
activity does not occur randomly within a population, but rather
is an intrinsic property of all cells in this culture.
To determine if the decreased transcription associated with
mutations at position 627 was the result of a general polymerase
defect or a host-specific restriction, we performed polymerase
activity assays in avian cells. Western blotting showed similar
levels of NP and WT or mutant PB2 for each assay, indicating
equivalent transfection efficiency (Figure 1C). Polymerase activ-
ity of all PB2 mutants restricted in human cells was significantly
enhanced in both chicken DF1 cells and quail QT6 cells
(Figure 1C). Specifically, PB2 K627E increased from 2.5%
WT activity in primate cells to over 70%WT activity in avian cells.
PB2 K627D transcription was also increased, but this mutant still
displayed only modest activity. Together, these data demon-
strate that a variety of mutations are tolerated at PB2 residue
627 for the production of functional polymerase in avian cells.
Thus, the predominance of glutamic acid at position 627 in avian
influenza populations (Chen et al., 2006a) is not due solely tor Inc.
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Production by Regulating Polymerase Activity in
Human Cells
(A) Recombinant A/WSN/33 virus was produced in 293T cells
expressing WT or K627E PB2. Viral titers (plaque-forming
units (pfu)/ml) were measured by plaque assays on MDCK
cells (n = 2–3 ± SD) before and after normalizing inoculums
based on hemaggluttination units.
(B) Viral polymerase activity was determined in primate cells
transfected with expression plasmids for PB1, PA, NP, the
indicated PB2-TAP, and a vRNA-luciferase reporter plasmid.
Control cells were transfected with reporter plasmid alone.
Luciferase activity was determined in cell extracts. PB2-
TAP and NP-V5 were detected by western blot. Molecular
weights are shown in kilodaltons.
(C) Polymerase activity assays were performed in the avian
cells as in (B), except the vRNA-luciferase reporter was
driven by a chicken pol I promoter. For all activity assays,
n = 3 ± SD.Cell Host & Microbe 4, 111–122, August 14, 2008 ª2008 Elsevier Inc. 113
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Restriction of the Influenza Virus PolymeraseFigure 2. A Dominant Inhibitory Activity Restricts PB2 Function in Human Cells
(A) Experimental strategy for formation of heterokaryons by expression of the fusogenic VSV-G protein. Heterokaryon formation between 293T cells expressing
GFP and DF1 cells expressing RFP was monitored by the detection of dual-fluorescent cells (arrowheads).
(B) Polymerase activity in heterokaryons expressing NP, PB1, PA, and no PB2, WT, or K627E PB2-TAP was determined by luciferase assay. Protein expression
was monitored by western blot. n = 3 ± SD.a requirement for polymerase activity, but might result from
additional selective pressures to maintain glutamic acid at this
position. Furthermore, the activity of these mutants in avian cells
suggests that their decreased activity in primate cells does not
reflect an intrinsic defect in polymerase function, but rather
represents a species-specific restriction.
Recent clinical specimens of H5N1 isolated from lethal human
infections possess the avian-signature glutamic acid at position
627 in PB2, but a small fraction also has an asparagine at posi-
tion 701, versus the aspartic acid typical of human strains (de
Jong et al., 2006). It is possible that the D701N change might
compensate for the decreased polymerase activity associated
with glutamic acid at position 627 in humans. However, the poly-
merase activity of the double mutant PB2 K627E/D701N re-
mained significantly impaired in 293T and Cos7 cells, with activ-
ity similar to PB2 K627E (Figure 1B). The double mutation did not
enhance activity in quail QT6 cells, whereas the pairedmutations
completely restored activity to WT levels in chicken DF1 cells
(Figure 1C). These results suggest that in some hosts these
changes might represent compensatory mutations, but in pri-
mate cells the conversion of position 701 to asparagine does
not compensate for the defects caused by PB2 K627E mutation
in the context of the A/WSN/33 polymerase.
The species-restricted functionality of PB2 K627E suggests at
least two possibilities: permissive avian cells might contain a fac-
tor or activity that compensates for an inherent defect associ-114 Cell Host & Microbe 4, 111–122, August 14, 2008 ª2008 Elsevieated with PB2 K627E, or nonpermissive primate cells contain
an activity that selectively impairs these polymerases. We tested
these two possibilities with a transient heterokaryon assay in
which human and avian cell hybrids were formed by the fuso-
genic VSV-G protein (Figure 2A). If avian cells contain a compen-
satory activity, DF1 cells expressing vRNA-luciferase are
predicted to rescue the activity of polymerase-containing PB2
K627E expressed in restrictive human cells upon fusion. Con-
versely, if human cells contain an inhibitory activity, fusion of
293T cells expressing vRNA-luciferase to polymerase-express-
ing avian cells is predicted to impair the otherwise functional
PB2 K627E. Critically, replication complexes only form in cells
that have undergone fusion. Fusion efficiency was monitored
by the appearance of dual-fluorescent cells in parallel experi-
ments where donor and acceptor cells expressed RFP and
GFP, respectively (Figure 2A). Fusion of donor DF1 cells to
293T cells expressing polymerase reconstituted polymerase ac-
tivity for WT PB2, but not PB2 K627E (Figure 2B). Activity of the
PB2 K627E polymerase was similar to the activity observed in
the absence of PB2, which was less than that observed in donor
DF1 cells alone. No polymerase activity was observed in unfused
cells (data not shown). These data suggest that avian cells do not
contain an activity or factor that compensates for mutations at
PB2 residue 627. Fusion of donor 293T cells to DF1 cells recov-
ered polymerase activity for WT polymerase, but severely im-
paired the function of polymerase-containing PB2 K627Er Inc.
Cell Host & Microbe
Restriction of the Influenza Virus PolymeraseFigure 3. Avian-like PB2 Mutants Form Trimeric Polymerase Complexes in the Nucleus
(A) Influenza polymerase was TAP-tag purified from nuclear extracts of 293T cells expressing PB1, PA, and PB2-TAP. Proteins were detected by Coomassie
staining.
(B) Subcellular localization of PB1 and PB2 were determined by western blotting of nuclear (N) and cytoplasmic (C) extracts prepared from 293T cells transfected
with expression vectors for PB1-TAP, PA, and the indicated PB2-TAP. The identity of each fraction was confirmed by western blotting for tubulin, a cytoplasmic
protein, and TATA-binding protein (TBP), a nuclear protein. Molecular weight is shown in kilodaltons.(Figure 2B). PB2 K627E polymerase activity was reduced to
background levels, compared to the 70% activity displayed
by this mutant when reporter assays were performed in unfused
DF1 and QT6 cells (Figure 1C). Similar results were observed
when heterokaryon formation was mediated by polyethylene
glycol (Figure S4). Western blotting of lysates from mixed cell
cultures shows equivalent levels of WT and mutant PB2-TAP
and NP, indicating that the lack of polymerase activity did not
result from changes in protein stability upon heterokaryon forma-
tion (Figure 2B). Together, these data provide strong evidence
that human cells contain an activity that selectively inhibits
polymerase with the avian-signature PB2 K627E.
Polymerases Containing Mutant PB2 Assemble
and Localize to the Nucleus
The heterokaryon assays suggest the presence of an activity in
primate cells that restricts the function of the avian-like PB2
K627E polymerase, but do not indicate the specific molecular
defects associated with this inhibition. One possible explanation
is a failure to assemble the trimeric polymerase complex. To test
this possibility, we purified WT and K627E PB2-TAP polymerase
complexes from 293T cell nuclear extracts. Both WT andmutant
PB2-TAP coprecipitated approximately stoichiometric amounts
of PB1 and PA (Figure 3A and data not shown). PB1 and PA
migrate at similar positions in this gel system and have been
identified by mass spectrometry in similar experiments (data
not shown). Thus, PB2 K627E does not prevent assembly of
the trimeric viral polymerase.Cell HoAnother possible explanation is alteration of the subcellular
localization of mutant polymerase. Influenza polymerase-cata-
lyzed transcription and viral replication occurs within the nucleus
of infected cells (Herz et al., 1981; Jackson et al., 1982). The
polymerase subunits rely on cellular proteins for nuclear import,
and changes in the C terminus of PB2 have been associated with
species-specific defects in subcellular localization (Gabriel et al.,
2008; Naito et al., 2007). Therefore, we assayed the subcellular
distribution of various polymerase complexes. Western blotting
of nuclear and cytoplasmic fractions of 293T cells shows that
all PB2 variants localized almost exclusively in the nucleus
(Figure 3B). PB1 colocalized with the PB2 variants, consistent
with the ability of mutant PB2 to associate with PB1 and PA as
demonstrated above. Control western blots for proteins found
primarily in the cytoplasm (tubulin) and the nucleus (TATA-bind-
ing protein) confirm the identity of the subcellular fractions and
demonstrate minimal crosscontamination (Figure 3B). These
data indicate that mutation of PB2 residue 627 does not prevent
polymerase assembly or proper subcellular localization.
PB2 K627E Mutation Impairs Assembly of
Ribonucleoprotein Complexes without Disrupting
the NP-Binding Site
Assembly of the vRNP, a complex consisting of vRNA coated by
NP and the polymerase, is essential to both viral replication and
transcription. NP is a major structural protein that binds both
vRNA and cRNA and interacts with the PB1 and PB2 subunits
to facilitate polymerization (Biswas et al., 1998; Medcalf et al.,st & Microbe 4, 111–122, August 14, 2008 ª2008 Elsevier Inc. 115
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position 627 was found to immunoprecipitate lower amounts of
NP in human cells relative to that observed for a mutant contain-
ing lysine at this position (Labadie et al., 2007). We confirmed
that the inhibitory activity in human cells correlates with
decreased RNP assembly; WT polymerase was specifically co-
precipitated by NP, whereas precipitation of PB2 K627E poly-
merase was significantly decreased (Figure 4A). Treatment of
cell lysates with RNase—and the presumptive disassembly of
vRNPs—did not restore interaction between NP and PB2
K627E (Figure 4A), suggesting that the binding defect is largely
independent of vRNA. The low amounts of PB2 K627E precipi-
tated by NP might account for the low infectious titers and activ-
ity of this polymerase detected in 293T cells (Figure 1). Similar
results were observed in reciprocal immunoprecipitations,
where significantly less NP was precipitated by polymerase con-
taining PB2 K627E compared to WT (Figure 4A). However, WT
and PB2 K627E polymerase were equally precipitated from
lysates prepared from transfected avian DF1 cells (Figure 4B).
The chaperone protein Hsp90 has been identified as a cellular
cofactor in polymerase assembly (Naito et al., 2007). WT and
mutant PB2 both coprecipitated Hsp90 from 293T cell extracts,
indicating that assembly defects are not simply the result of a
failure to bind Hsp90 (Figure S5).
PB2 interacts with NP independent of PB1 and PA, possibly
via a C-terminal binding region that might encompass amino
acid 627 (Biswas et al., 1998; Medcalf et al., 1999; Poole et al.,
2004). To further probe the binding between NP and PB2
K627E, we expressed only these two proteins in 293T and DF1
cells. To our surprise, and in contrast to previous results (Labadie
et al., 2007), WT and PB2 K627E were immunoprecipitated at
similar levels when expressed in either human or avian cells
(Figures 4C and 4D). Thus, PB2 K627E is competent to bind
NP when expressed alone, but not in the context of the trimeric
holoenzyme. Furthermore, these data suggest that changes at
amino acid 627 do not disrupt the NP-binding site(s) on PB2.
Consequently, these results suggest that the species-restricted
activity of PB2 K627E is the result of a defect(s) in polymerase
assembly or conformation that precludes binding to NP within
the vRNP complex.
To directly assess the consequences of defective vRNP as-
sembly on enzyme activity, we measured the products of
vRNA replication (vRNA and cRNA) and transcription (mRNA).
Primer-extension assays were performed on total RNA extracted
from 293T cells expressing the polymerase, NP, and the vRNA-
luciferase reporter. Both plus-sense andminus-sense viral RNAs
were detected in the presence of WT polymerase, but not in un-
transfected cells (Figure S6). Viral mRNA is the predominant
species, as previously reported (Fodor and Smith, 2004). Similar
results were obtained when probes were used alone or in com-Cell Hbination; therefore, tandem primer-extension analysis was per-
formed to analyze viral RNAs. Primer extension demonstrates
that both WT and PB2 K627R polymerase synthesized signifi-
cant amounts of mRNA, cRNA, and increased levels of vRNA,
quantified at 2.3- and 1.9-fold, respectively, over that of the re-
porter vector alone (Figure 4E). This is consistent with the high
levels of luciferase detected in the polymerase-activity assays
in human cells (Figure 1B). By contrast, only low levels of
mRNAwere detected in the presence of PB2 K627A, and no syn-
thesis of any viral RNAs was detected above background in the
presence of PB2 K627D or K627E (Figure 4E). vRNA, cRNA, and
mRNA were detected in DF1 cells expressing WT or PB2 K627E
polymerase (Figure 4E), indicating that WT and mutant PB2 sup-
port both replication and transcription of viral RNAs in avian cells.
Quantification shows that PB2 K627E produces 80% of the
mRNA product compared to WT (data not shown), in agreement
with results from the polymerase-activity assays (Figure 1C).
These data demonstrate that species-restricting mutations
in PB2 prevent both replication and transcription of vRNA in
human, but not avian, cells. mRNA is produced shortly after in-
fection (Glass et al., 1975); thus, it appears that inhibition of bind-
ing of PB2 K627E polymerase to NP disrupts one of the earliest
steps of viral infection.
Recovery ofMutant PB2 Function during Virus Assembly
Because the block to PB2 K627E activity in primate cells occurs
during the early stages of viral gene expression and genome rep-
lication, we next tested whether coexpressing WT PB2 can by-
pass an early blockade and rescue activity of PB2 K627E during
later stages of virus production. Recombinant virus was pro-
duced in 293T cells by transfection of a genomic expression vec-
tor and plasmids encoding NP, PB1, PA, PB2, and an equivalent
amount of WT or mutant PB2-TAP where indicated. Western blot
analysis of cell lysates indicated that PB2 and PB2-TAPwere ex-
pressed in virus-producing cells (Figure 5A). BothWT and K627E
PB2-TAP were detected in cell-free virions harvested at 24 hr
(Figure 5A), 48 hr, and 72 hr posttransfection (data not shown).
Thus, even though our data indicate that PB2 K627E is defective
at early stages of virus replication, it is still packaged into virions
at levels similar to WT PB2-TAP when untagged PB2 is coex-
pressed, raising the possibility that the defects associated with
K627E might be absent during late stages of infection or allevi-
ated by WT PB2.
To further test this hypothesis, we assayed binding between
PB2-TAP and NP in virus-producing cells (Figure 5B). WT and
K627E PB2-TAP coprecipitated NP at similar relative amounts
from cell lysate, providing further evidence that the K627E mu-
tant is functional during late stages of virus production. This is
in contrast to the extremely low amounts of NP coprecipitated
when PB2 K627E polymerase was expressed without WT PB2Figure 4. PB2 K627E Mutation Prevents Assembly of vRNP without Disrupting the NP-Binding Site
(A and B) Cell lysates prepared from 293T (A) or DF1 (B) cells transfectedwith expression vectors for PB1, PA, NP,WT or K627E PB2-HA, and the vRNA-luciferase
reporter were subject to immunoprecipitation and western blotting. Where indicated, lysates were treated with RNase.
(C and D) Immunoprecipitations and western blots were performed on lysates from 293T (C) and DF1 (D) cells expressing NP and WT or K627E PB2. The levels
and ratio of PB2 and NP were the same as in (A) and (B).
(E) Primer-extension assays were used to detect RNAs produced in 293T cells or DF1 cells expressing viral polymerases containing WT or mutant PB2 in the
presence of a vRNA-reporter. Products are indicated, and the size of a DNA standard is shown in nucleotides. A nonspecific band (*) serves as an internal loading
control.ost & Microbe 4, 111–122, August 14, 2008 ª2008 Elsevier Inc. 117
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(A) Recombinant virus was produced in 293T cells transfectedwith pTM-pol I-WSN-All and expression vectors for NP, PB1, PA, PB2, andWT or K627E PB2-TAP.
PB2 and PB2-TAP were detected by western blot of cell lysate or cell-free virions with anti-PB2 serum.
(B) PB2-TAP was precipitated with rabbit IgG-agarose from virus-producing cell lysates. Coprecipitating NP was detected by anti-NP western blot.
(C) Purified virus was lysed and separated on a linear 30%–60% glycerol gradient. Where indicated, 1% deoxycholate (DOC) was present during viral lysis.
Fractions were collected, and PB2 and NP were detected by western blot. Nonspecific bands (*) at the top of the gradient are indicated.(Figure 4A). To eliminate the possibility that NP coprecipitation
was due to PB2-TAP that was not assembled into a trimeric poly-
merase complex or that virion-associated PB2-TAP was
nonspecifically packaged, we analyzed the incorporation of
PB2-TAP into vRNPs within virions. Glycerol-gradient centrifu-
gation was performed using vRNPs isolated from cell-free
virions. Free, nonspecifically incorporated polymerase is pre-
dicted to remain at the top of the gradient, whereas polymerase
associated with vRNPs migrates into the gradient (Klumpp et al.,118 Cell Host & Microbe 4, 111–122, August 14, 2008 ª2008 Elsevie2001). Similar amounts of lysed viral cores were separated on
a linear 30%–60% glycerol gradient, and fractions were ana-
lyzed by western blot (Figure 5C). WT PB2 migrated into the gra-
dient and cosedimented with fractions containing the majority of
NP. As expected, free PB2 released from vRNPs by treatment
with 1% deoxycholate remained at the top of the gradient. By
contrast, glycerol gradients of viruses containing WT PB2 in
combination with WT or K627E PB2-TAP demonstrate that the
PB2-TAP variants migrated into the gradient with a profile similarr Inc.
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although less PB2-TAP was packaged into virions compared to
untagged PB2, PB2-TAP still sedimented with vRNPs. These
results indicate that WT and K627E PB2-TAP polymerases are
incorporated into virions as vRNPs. This is consistent with our
earlier observation that virions containing a PB2 K627E polymer-
ase were equally infectious compared to those with a WT poly-
merase once normalized to hemagglutinin content, even though
the overall infectious viral titers were reduced 100-fold (Figure 1).
Together, these data suggest that the inhibitory activity targeting
PB2 K627E is absent during virus assembly and budding.
DISCUSSION
Cross-species transmission of influenza from birds to humans
requires the adaptation of viral genes to the new host. Several
species-specific determinants of viral replication and pathoge-
nicity have been identified, including adaptations in HA that en-
hance processing and govern receptor specificity, NS1 se-
quences that deregulate innate antiviral responses, and a point
mutant in PB2 that increases nuclear localization in human cells
(Gabriel et al., 2008; Govorkova et al., 2005; Hatta et al., 2001;
Jackson et al., 2008; Krug, 2006). We have shown here that
changeswithin the PB2 subunit of the influenza virus polymerase
are necessary to overcome an inhibitory activity or factor in hu-
man cells that selectively restrict the function of an avian-like
polymerase. This inhibitory activity prevents assembly of vRNPs,
thereby disrupting genomic replication and the production of
viral mRNA, a critical step early in virus replication. This potent
block early in infection suggests that an inhibitory factor is pres-
ent in mammalian cells prior to infection, perhaps constitutively
expressed. However, the inhibitory effect is relieved during later
stages of the viral life cycle. Virions that were produced by PB2
K627E polymerase were as infectious asWT, suggesting that re-
sidual polymerase activity was sufficient tomake new virions and
that the processes of vRNP export, virion assembly, and bud-
ding are unaffected by the species-specific restriction. The abil-
ity of WT PB2 to rescue the function of PB2 K627E during virus
production also indicates that the blockade does not target mu-
tant PB2 during late stages of replication. Thus, transmission of
virus from birds to humans is restricted in part by an innate
activity in human cells that disrupts polymerase function early
in infection.
Several host cofactors have been identified that interact with
the polymerase and nucleoprotein (Deng et al., 2006; Engelhardt
et al., 2005; Gabriel et al., 2008; Huarte et al., 2001; Kawaguchi
andNagata, 2007;Mayer et al., 2007;Momose et al., 2001, 2002;
Naito et al., 2007; Tarendeau et al., 2007). However, few interact
directly with PB2 and of those that do, binding is independent of
changes at position 627 (Figure S5) (Gabriel et al., 2008). Inhibi-
tory activity may bemediated directly by an antiviral factor exclu-
sive to primates that specifically targets PB2, or possibly a more
fortuitous blockade by a cellular activity affecting viral proteins. It
also remains possible that this activity results from evolutionarily
divergent forms of a protein factor common to avian and primate
hosts. The change in restriction during the viral life cycle may re-
sult from alterations in cellular protein function, possibly due to
repression of host-protein production during viral infection
(Krug et al., 1989), or changes to viral proteins that influenceCell Hpolymerase activity and susceptibility to the inhibitor. It is of
great interest to determine if the inhibitory activity is due to bind-
ing by a host factor, binding by a small molecule, modification by
a host factor, or some indirect effect on vRNP assembly.
Adaptation is a multigenic process, and other mutations within
the influenza-replication machinery also enhance replication in
mammalian hosts. Whereas position 627 in PB2 is a key regula-
tor of species-specific polymerase activity, replication and path-
ogenicity are not always strictly correlated with the presence of
lysine at PB2 627 (Gabriel et al., 2005; Gao et al., 1999; Govor-
kova et al., 2005). For example, recent infections in humans
with avian H5N1 display a 60% case fatality rate, despite
many of these viruses retaining a glutamic acid at residue 627.
Other changes may partially overcome defects associated with
a glutamic acid at PB2 residue 627; the PB2 D701N and NP
N319K mutations enhanced polymerase activity and lethality in
the mouse-adapted H7N7 isolate SC35M in mammalian hosts
even though this virus contains a glutamic acid at residue 627
in PB2 (Gabriel et al., 2005). The same PB2 D701N mutation
was observed in lethal infections with H5N1 viruses that posses
PB2 with glutamic acid at residue 627 (de Jong et al., 2006).
However, the PB2 D701N mutation did not rescue polymerase
activity of a PB2 K627E polymerase derived from the A/WSN/33
strain (Figure 1). Furthermore, introducing a lysine at amino
acid 627 in PB2 of the parental SC35 virus increased polymerase
activity 20-fold, compared to the more modest 6-fold increase
associated with PB2 D701N (Gabriel et al., 2005). The varied ef-
fects of mutations in different viral strains and cells highlight the
complex interplay between the subunits of the viral-replication
machinery and between the replication machinery and the host.
PB2 K627E binds to NP in human cells when expressed alone,
but not when assembled into the trimeric polymerase (Figure 4),
raising the possibility that the glutamic acid-to-lysine change
might induce conformational alterations within the holoenzyme
with species-specific consequences. Structural models of the
influenza polymerase generated by electron microscopy sug-
gest large-scale conformational rearrangements within the poly-
merase that occur upon vRNP formation, specifically changes
including PB2 and regions that bind NP (Area et al., 2004;
Torreira et al., 2007). In this scenario, trimeric polymerases con-
taining PB2 K627E might adopt a conformation that precludes
the conformational changes required for NP binding and vRNP
assembly in mammalian cells. This is consistent with the fact
that residue 627 lies outside of all known protein-binding sites
in PB2. This alternative conformation could be influenced by
species-specific binding partners or posttranslational modifica-
tions. For example, studies have shown that the enhancement
of polymerase activity and virus lethality associated with the
PB2 D701N mutant results from changes in conformational
flexibility that increase binding to the nuclear import adaptor
importin a1 in a species-specific fashion (Gabriel et al., 2008;
Tarendeau et al., 2007). A better understanding of the conforma-
tional changes the polymerase undergoes upon vRNP formation
might inform on the assembly defect manifest by the PB2 K627E
mutation.
The potent block to avian-like influenza polymerase during
early stages of viral replication in human cells provides a strong
selective pressure for PB2 mutations. Indeed, virtually all strains
of influenza that have circulated in humans contain PB2 withost & Microbe 4, 111–122, August 14, 2008 ª2008 Elsevier Inc. 119
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tide change in avian PB2 vRNA results in an adaptive mutation
that introduces a lysine at amino acid 627 and restores polymer-
ase activity in mammalian cell culture (Figure 1), viral replication
in animal models (Hatta et al., 2001; Munster et al., 2007; Salo-
mon et al., 2006; Subbarao et al., 1993), and is often associated
with increased replication and lethality in humans (Clements
et al., 1992; Hatta et al., 2001; Munster et al., 2007; Salomon
et al., 2006). Escape from this species-restricting factor is also
a hallmark of the pandemic 1918 strain (Taubenberger et al.,
2005). These findings indicate that mutations in PB2 play a key
role in the evolution of influenza as it is transmitted from birds
to humans. However, it remains to be determined whether the
vRNP assembly defects displayed in human cells by PB2 with
a glutamic acid at residue 627 from the A/WSN/33 strain
(Figure 4) or the primary avian isolate A/Mallard/Marquenterre/
MZ237/83 (Labadie et al., 2007) are generally applicable to other
primary isolates, especially lethal H5N1 isolates that retain a glu-
tamic acid at this residue (Gao et al., 1999). Regardless, it is
alarming to note that many of the viruses isolated during a recent
outbreak of H5N1 virus infection in wild birds contained PB2with
a lysine at position 627 (Chen et al., 2006b). Thus, viruses with
adaptive mutations for replication in humans are circulating in
migratory waterfowl populations.
In summary, we demonstrate that an inhibitory activity in hu-
man cells restricts the function of influenza polymerase contain-
ing an avian-like PB2 by preventing assembly of polymerase into
the vRNP. This assembly defect reduces virion production by
blocking replication and transcription of viral RNAs. It also likely
represents amajor barrier to cross-species transmission of influ-
enza from birds to humans. Determining the mechanisms of re-
striction will provide crucial insight into virus-host interactions
and factors influencing the infectivity and relative pathogenicity
of viruses newly transferred into humans, and may ultimately
identify new targets for therapeutic intervention.
EXPERIMENTAL PROCEDURES
Reagents
The plasmids pCDNA-PA, pCDNA-PB1, pCDNA-PB1-TAP, pCDNA-PB2, and
pCDNA-PB2-TAP derived from influenza A/WSN/33 have been described
(Engelhardt et al., 2005). pCDNA-NP-V5 and pCMV4-PB2-HA were con-
structed with cDNA derived from A/WSN/33. pCAGGS-WSN-NP 0/12 and
the vRNA expression vector pTM-polI-WSN-All were gifts of Y. Kawaoka
(Neumann et al., 2005). pTM-DPB2 was created by excising the PB2-expres-
sion cassette from pTM-polI-WSN-All. pBD-PB2 and pBD-PB2 K627E are
bidirectional expression constructs for production of PB2 (A/WSN/33) vRNA
and mRNA based on pHW2000 (Hoffmann et al., 2000). The vRNA-luciferase
reporter plasmid, pHH21-vNA-luc, contains the luciferase-coding sequence
in the antisense orientation flanked by the 50 and 30 untranslated regions of
the vNA gene segment from the A/WSN/33 isolate and was previously de-
scribed (Regan et al., 2006). The vRNA-luciferase reporter plasmid used in
avian cells, pgHH21-vNA-luc, was created by replacing the human pol I pro-
moter of pHH21-vNA-luc with a minimal chicken pol I promoter (Massin
et al., 2005) constructed de novo from oligonucleotides. pVSV-G was pur-
chased from Clontech. PB2 mutants were created by PCR-based strategies
and confirmed by sequencing.
Immunoreagents include anti-protein A (Sigma), anti-NP (ATCC hybridoma
HB-65), anti-V5 (Bethyl Laboratories), anti-HA (Roche), anti-TBP (BioDesign),
anti-tubulin (Sigma), protein A-agarose (Sigma), and rabbit-IgG agarose
(Sigma). PB2 antiserum was created by immunization of rabbits with
His6-PB2(1-156) purified from E. coli (Josman, LLC).120 Cell Host & Microbe 4, 111–122, August 14, 2008 ª2008 ElsevieAll cells were maintained in Dulbecco’s modified Eagle’s medium supple-
mented with 10% FBS. Cells were transfected with FuGene6 (Roche) or
calcium phosphate. Luciferase assays were performed according to the man-
ufacturer’s instructions (Promega). Cytoplasmic and nuclear fractions were
isolated with the NE-PER Kit (Pierce). Immunoprecipitations were performed
with cell lysates prepared in 50 mM Tris (pH 7.4), 50 mMNH4Cl, 15% glycerol,
and 0.5% NP40. Purification of TAP-tagged polymerase was as described
(Engelhardt et al., 2005).
Primer Extension
RNA was extracted from 293T or DF1 cells 48 hr after transfection with
pCDNA-PB1, pCDNA-PA, pCDNA-NP-V5, and WT or mutant pCDNA-PB2
and pHH21-vNA-luc or pgHH21-vNA-luc. Primer-extension assays were per-
formed using radiolabeled probes directed against luciferase (Fodor and
Smith, 2004). Products were resolved on 8% polyacrylamide gels containing
7 M urea and detected and quantified by phosphorimaging.
Virus Production
Recombinant virus was produced in 293T transfected with pTM-DPB2,
pCAGGS-WSN-NP 0/12, pCDNA-PA, pCDNA-PB1, and pBD-PB2 or
pBD-PB2 K627E. Virus was harvested 48 hr posttransfection. Hemagglutina-
tion activity was measured using a 0.5% solution of turkey red blood cells, and
the infectious titer was determined on MDCK cells. Recombinant virus was
also produced in the presence of PB2-TAP by transfecting 293T cells with
pTM-polI-WSN-All, pCAGGS-WSN-NP 0/12, pCDNA-PA, pCDNA-PB1,
pCDNA-PB2, and pCDNA-PB2-TAP WT or K627E. Virus was harvested 24
hr later, and vRNPs were fractionated on a linear 30%–60% glycerol gradient
as described (Klumpp et al., 2001).
Heterokaryon Formation
Donor cells were transfected with pHH21-vNA-luc (293T cells) or pgHH21-
vNA-luc (DF1 cells). Separately, acceptor cells were transfected with
pCDNA-PB1, -PA, -PB2, -NP-V5, and pVSV-G. Transfected cells were incu-
bated overnight and washed extensively. Donor cells were trypsinized and
mixed with acceptor cells at a 1:1 ratio. Heterokaryon formation was moni-
tored visually with donor and acceptor cells expressing RFP and GFP, respec-
tively. Cells were harvested 30 hr after mixing and subject to luciferase
assays and western blot.
SUPPLEMENTAL DATA
Supplemental Data inlude six figures and can be found online at http://www.
cellhostandmicrobe.com/cgi/content/full/4/2/111/DC1/.
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